Analyst Thomas Shrader of BTIG maintained a Buy rating on Arcturus Therapeutics, with a price target of $23.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Thomas Shrader has given his Buy rating due to a combination of factors related to Arcturus Therapeutics’ ongoing developments and financial position. The company’s ARCT-032 program for cystic fibrosis has shown promising results in reducing mucus deposits in patients’ lungs, which has been well-received by the CF community. This positive reception has reinforced the decision to continue developing ARCT-032, with a new trial planned for next year focusing on Type 1 patients, who are seen as the most likely candidates for drug approval.
Additionally, Arcturus Therapeutics has a strong financial position, ending the third quarter with $237.3 million in cash, providing a financial runway until 2028. The company’s vaccine platform, particularly its SAM-RNA approach, is also noteworthy as it aims to address safety concerns associated with mRNA vaccines, potentially attracting significant support. These factors, combined with the positive readout of their ARC-810 platform, suggest a promising outlook for the company, justifying the Buy rating.
According to TipRanks, Shrader is a 3-star analyst with an average return of 2.6% and a 38.40% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Harrow Health, Stoke Therapeutics, and Gain Therapeutics.